Video

Dr. Palmbos on the Utilization of Nivolumab Following Cystectomy in Muscle-Invasive Bladder Cancer

Phillip Palmbos, MD, PhD, discusses the utilization of adjuvant nivolumab following cystectomy in high-risk, muscle-invasive bladder cancer.

Phillip Palmbos, MD, PhD, assistant professor, University of Michigan Health, discusses the utilization of adjuvant nivolumab (Opdivo) following cystectomy in high-risk, muscle-invasive bladder cancer. 

The randomized phase 3 CheckMate 274 trial (NCT02632409) examined nivolumab vs placebo in this patient population, Palmbos says. High-risk patients in this trial were defined as those with node-positive disease at cystectomy, T2 or greater for patients who underwent prior neoadjuvant chemotherapy, or T3 or greater with no history of neoadjuvant chemotherapy, Palmbos adds. 

The primary end point of disease-free survival was met, particularly in the in the PD-L1–positive population, Palmbos adds. For patients with high-risk features observed in the CheckMate 274 study, nivolumab could have a role in the adjuvant setting following cystectomy, Palmbos concludes.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity